All News
#EULAR2024 OP0149 When the Doctor says YES but the patients say NO. Data from UK BILAG-BR in moderate to severe #lupus showed ~half patients who met clinical response did not improve their psychological wellbeing. Factors of discordant: ancestry, damage, SLEDAI-2K @RheumNow https://t.co/9cqcPripA2
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts with SLEDAI=0 + pred =<5mg/d + stable IS/HCQ, GC discontinuation after proper tapering appeared safe and was associated with a low risk of flare @RheumNow https://t.co/8IIgPuZUrF
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0187 Can we identify a subgroup of #lupus patients at the outset who may benefit from early intensive therapies inc biologics? Data from an inception cohort showed low complement & cSLEDAI=>9 were assoc w increased risk of intensive therapy need/Tx failure @RheumNow https://t.co/jmahjcqom3
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
New targets and new treatments in #Sjogren’s disease:
Long term outcomes of repeat cycles of RTX
#EULAR2024
CB https://t.co/6fL3e33i8N
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
STAR responder may be the way to go! Less placebo effect than CREST.
Better in patients with low systemic activity. https://t.co/mMYOKfG2gS
Links:
Bella Mehta bella_mehta ( View Tweet)
A fantastic tool LupusGPT by @LupusEurope for our patients to help self-manage #SLE was launched yesterday. Building on information from Lupus100 & supplemented by scientific data and relevant guidelines. I have tried it and worked well. Please disseminate https://t.co/a1qXGZyRE6 https://t.co/LTQM6A8Zq3
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
New drug TAK-279 (zasocitinib) shows promise for #PsA Significantly improved symptoms in patients after 12 weeks compared to placebo & well-tolerated.
Fewer targeted oral therapies exist, making zasocitinib a potential new option. #EULAR24 #PsA
IH https://t.co/RvcONHCLvz
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
Today, on National Career Nursing Assistants Day, we celebrate the nursing assistants who enhance the lives of our families and loved ones every day! Take a moment to express your gratitude for their care and hard work. #CareerNurseAssistantsDay https://t.co/Mijr820gnE
Rheumatology Nurses RNSociety ( View Tweet)
40% women above 60yo have #osteoarthritis. 25% have hand OA #EULAR24 https://t.co/9ZaQYIYIxn
Vasco C Romao romaovc ( View Tweet)
predict secukinumab response but left out half of patient population ? selection bias @rheumnow #EULAR2024 https://t.co/K4J6eQV0zh
Peter Nash drpnash ( View Tweet)
#EULAR2024
21-24% of #APS patients have #metabolic syndrome
Also ⬆️ rates if atherosclerotic plaque progression in pts with #AntiPhospholipidSyndrome
#CVD #IHD #ASCVD
By @MariaTektonidou https://t.co/EZsxJE7YJa
Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
Fantastic presentation from @MiaRodziewicz using BILAG-BR data:
⭐️NPSLE had higher damage / disease activity
⭐️ NPSLE more likely to have APS ab
⭐️ RTX appears effective in NPSLE (no trials) https://t.co/25984cORj0
Sarah Dyball sarahdyball1 ( View Tweet)
Great results presented at #EULAR24 by Greg Dresler on CD19/BCMA CAR T-cell therapy. 18 additional SLE patients with great response. @LUPUSDK @LupusEurope https://t.co/2C64ECzq83
Anne Troldborg TroldborgAnne ( View Tweet)
Another excellent oral presentation from UPMC myositis center by Shiri Keret at #EULAR2024. She showed that many myositis patient may have normal CK despite muscle weakness. However, CK is associated with outcomes over time even in patients with normal or near normal CK,… https://t.co/nAoUo8fcXh https://t.co/J8iZG4eESP
Links:
Rohit Aggarwal docrota ( View Tweet)
✅ Updated pipeline of phase 2 & 3 trials in #Lupus ⬇️ #EULAR2024
Please let me know if something is missing or incorrect 👍 https://t.co/ruuKYmAvYj
Laurent ARNAUD Lupusreference ( View Tweet)
John H Stone’s #IgG4RD lessons:
1-It is a variable-vessel vasculitis
2-more common/severe in males (2:1)
3-Has no diagnostic histopathology
4-IgG4 does not cause IgG4RD
5-Serum igg4 is a good biomarker
6-Rising IgG4 shouldn’t be ignored
#EULAR2024 https://t.co/7p6pBqI4ue
Vasco C Romao romaovc ( View Tweet)
#EULAR2024 the benefit of in person conference. Meeting colleagues IRL @KDAO2011 @RADoctor https://t.co/g0JH5s0mcD
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RA specific bone signatures (markers) detected by machine learning. Abst#0125
Dkk1 increased in erosive RA #EULAR2024 @RheumNow https://t.co/0A5C9LCzle
Bella Mehta bella_mehta ( View Tweet)
Fibroblasts activated -> secrete chemokines which lead to granzyme K production inturn leading to damage to mitochondria - release of mitochondrial DNA and production of interferon type 1 which ultimately lead to infiltrates (which contribute to the worsening saliva production) https://t.co/jZkU3SBhwc
Links:
Bella Mehta bella_mehta ( View Tweet)